Table 3.
Transplant outcomes of the intervention group according to the number of feedback messages generated
| Feedback ≥1 (n = 13) | No feedback (n = 38) | p value | |
|---|---|---|---|
| Drug levels | |||
| TAC trough level, ng/mL | 5.1 ± 1.2 | 5.3 ± 1.1 | 0.574 |
| TAC CVa | 29.4 ± 16.3 | 22.1 ± 12.0 | 0.155 |
| MPA trough level, μg/mL | 2.4 ± 1.0 | 2.9 ± 1.8 | 0.332 |
| MPA CVa | 36.6 ± 24.8 | 38.3 ± 14.3 | 0.754 |
| eGFR | |||
| 4 weeks | 71.5 ± 21.9 | 66.6 ± 16.9 | 0.474 |
| 8 weeks | 69.8 ± 22.7 | 67.3 ± 18.8 | 0.720 |
| 12 weeks | 66.4 ± 21.0 | 66.8 ± 19.1 | 0.946 |
| 16 weeks | 66.6 ± 19.4 | 67.9 ± 16.9 | 0.829 |
| 20 weeks | 66.9 ± 22.2 | 66.1 ± 16.6 | 0.914 |
| 24 weeks | 65.7 ± 23.5 | 65.0 ± 17.4 | 0.928 |
| Number of events, n (%) | |||
| De novo anti-HLA antibodies | 1 (7.7) | 2 (5.3) | 0.748 |
| BK viremia | 0 (0) | 1 (2.6) | 0.555 |
| BPAR | – | – | |
| DCGL | – | – | |
Values are shown as mean ± standard deviation or number (%)
BPAR Biopsy-proven acute rejection, CV Coefficient of variation, DCGL Death-censored graft loss, eGFR estimated glomerular filtration rate, HLA Human leukocyte antigen, MPA Mycophenolic acid, TAC Tacrolimus
aCV = (standard deviation/mean) × 100%